Collectively, these limitations raise safety and translational concern prompting an urgent need for novel therapeutics targeting upstream regulators of NLRP3 activation that can effectively cross the BBB and modulate neuroinflammation in PD. Here, NLRP3 is linked to Parkinson disease.